A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension
2010 (English)In: ACTA OPHTHALMOLOGICA, ISSN 1755-375X, Vol. 88, no 1, 37-43 p.Article in journal (Refereed) Published
Purpose: To compare the effect of time on therapy, efficacy, tolerability and resource utilization of latanoprost or non-prostaglandin analogues (non-PGs) in patients who required a change in intraocular pressure (IOP)-lowering monotherapy. Methods: This open-label, multicentre study (Sweden, 19 sites; Finland, seven sites) included adults with glaucoma or ocular hypertension with mean diurnal IOP andgt;= 21 mmHg on ocular hypotensive monotherapy. Patients were randomized to latanoprost monotherapy or non-PG therapy (commercially available therapy other than a PG) and followed for 36 months. End-points included: time to treatment failure (baseline to visit with a change in/addition to treatment); diurnal IOP (mean of 08.00, 12.00 and 16:00 hr measurements) at months 6, 12, 24 and 36; tolerability; and resource utilization, where analyses used Swedish and Finnish 2006 unit costs. Results: Three hundred and twenty-six patients received andgt;= 1 dose of latanoprost (n = 162) or non-PGs (n = 164). Median time to treatment failure was longer for latanoprost (36 months) than for non-PGs (12 months; p andlt; 0.001); 51% and 24% of patients remained on randomized therapy after 36 months, respectively (p andlt; 0.001). Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p andlt; 0.01). No serious adverse events were judged to be treatment-related. Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs. Conclusion: Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost. Latanoprosts IOP-reducing effect and tolerability were sustained over the long term. Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.
Place, publisher, year, edition, pages
2010. Vol. 88, no 1, 37-43 p.
efficacy, glaucoma, health resource utilization, latanoprost, ocular hypertension, persistency, tolerability
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-54086DOI: 10.1111/j.1755-3768.2009.01663.xISI: 000274168900008OAI: oai:DiVA.org:liu-54086DiVA: diva2:298244